Attempts to develop a simple, objective test for oestrus in sows

To evaluate the accuracy of various techniques for determining the sexual state of sows, four multiparous Landrace sows were housed in stalls 2-5 weeks after weaning. Catheters were inserted under anaesthetic into a prominent ear vein on each sow. Four days later blood and urine sampling commenced, along with other measurements to assess the oestrous state of the animals. Oestrus was detected in all four sows and so were corresponding oestradiol·17β peaks (22-49 pg/ml) in serum of the three sows from which blood was successfully sampled during the complete 25·day collection period. Serum progesterone concentrations were highest between days — 5 and — 12 (day 0 = 1st day of standing heat) (peak values of 33·1-58·2 ng/ml), with values of 3·55 ng/ml or less on day 0. Urinary oestrogen was less well correlated with oestrous state than were serum hormone concentrations, but progesterone derivatives in urine corresponded well to serum progesterone with peaks between days —5 and —9. Vulval redness, vulval size, social interest and the occurrence of flehmen were markedly greater during the oestrous period than at other times in the cycle. Body temperature, vaginal pH, the presence of vaginal mucus and behavioural manifestations of oestrus (with the exception of back pressure test) were less well correlated with sexual state. A combination of vulval colour and size, back pressure test, a more detailed study of behaviour and possibly with urinary progesterone derivatives, should give the best indication of the incidence of oestrus in sow

A Measurement of Newton's Gravitational Constant

A precision measurement of the gravitational constant $G$ has been made using a beam balance. Special attention has been given to determining the calibration, the effect of a possible nonlinearity of the balance and the zero-point variation of the balance. The equipment, the measurements and the analysis are described in detail. The value obtained for G is 6.674252(109)(54) 10^{-11} m3 kg-1 s-2. The relative statistical and systematic uncertainties of this result are 16.3 10^{-6} and 8.1 10^{-6}, respectively.Comment: 26 pages, 20 figures, Accepted for publication by Phys. Rev.

Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients.

Expression of programmed death-ligand 1 (PD-L1) is the only routinely used tissue biomarker for predicting response to programmed cell death protein 1/PD-L1 inhibitors. It is to date unclear whether PD-L1 expression is preserved in brain metastases (BMs). In this single-center, retrospective study, we evaluated PD-L1 expression using the SP263 assay in consecutively resected BMs of lung carcinomas and paired primary tumors, diagnosed from 2000 to 2015, with correlation to clinicopathological and molecular tumor and patient characteristics. PD-L1 tumor proportional score (TPS) could be evaluated on whole tissue slides in 191 BMs and 84 paired primary lung carcinomas. PD-L1 TPS was less than 1% in 113 of 191 (59.2%), 1% to 49% in 34 of 191 (17.8%), and greater than or equal to 50% in 44 of 191 (23.0%) BMs. TPS was concordant between BMs and paired primary lung carcinomas in most cases, with discordance regarding the clinically relevant cutoffs at 1% and 50% in 18 of 84 patients (21.4%). Four of 18 discordant cases had no shared mutations between the primary lung carcinoma and BM. Intratumoral heterogeneity, as assessed using tissue microarray cores, was only significant at the primary site (p <sub>Wilcoxon signed rank</sub> = 0.002) with higher PD-L1 TPS at the infiltration front (mean = 40.4%, interquartile range: 0%-90%). Neither TPS greater than or equal to 1% nor TPS greater than or equal to 50% nor discordance between the primary lung carcinoma and BMs had prognostic significance regarding overall survival or BM-specific overall survival. PD-L1 expression was mostly concordant between primary lung carcinoma and its BM and between resections of BM and stereotactic biopsies, mirrored by tissue microarray cores. Differences in PD-L1 TPS existed primarily in cases with TPS greater than 10%, for which also human assessment tends to be most error prone

Operational Experience with a Cryogenic Axial-Centrifugal Compressor

The Large Hadron Collider (LHC), presently under construction at CERN, requires large refrigeration capacity at 1.8 K. Compression of gaseous helium at cryogenic temperatures is therefore inevitable. Together with subcontractors, Linde Kryotechnik has developed a prototype machine. This unit is based on a cryogenic axial-centrifugal compressor, running on ceramic ball bearings and driven by a variable-frequency electrical motor operating at ambient temperature. Integrated in a test facility for superconducting magnets the machine has been commissioned without major problems and successfully gone through the acceptance test in autumn 1995. Subsequent steps were initiated to improve efficiency of this prototype. This paper describes operating experience gained so far and reports on measured performance prior to and after constructional modifications

Weak ferromagnetism with very large canting in a chiral lattice: (pyrimidine)2FeCl2

The transition metal coordination compound (pyrimidine)2FeCl2 crystallizes in a chiral lattice, space group I 4_1 2 2 (or I4_3 2 2). Combined magnetization, Mossbauer spectroscopy and powder neutron diffraction studies reveal that it is a canted antiferromagnet below T_N = 6.4 K with an unusually large canting of the magnetic moments of 14 deg. from their general antiferromagnetic alignment, one of the largest reported to date. This results in weak ferromagnetism with a ferromagnetic component of 1 mu_B. The large canting is due to the interplay between the antiferromagnetic exchange interaction and the local single-ion anisotropy in the chiral lattice. The magnetically ordered structure of (pyrimidine)2FeCl2, however, is not chiral. The implications of these findings for the search of molecule based materials exhibiting chiral magnetic ordering is discussed.Comment: 6 pages, 5 figure

Inflammation in acute myocardial infarction: the good, the bad and the ugly.

Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare 'The Good' (repair and defence) while treating 'The Bad' (smouldering RIR) and capturing 'The Ugly' (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials

Inflammation in acute myocardial infarction: the good, the bad and the ugly

Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare ‘The Good’ (repair and defence) while treating ‘The Bad’ (smouldering RIR) and capturing ‘The Ugly’ (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials